Peter Attia on Thyroid Health: Why 5% of Adults Are Mismanaged, TSH Isn't the Full Picture, and What to Do When Tests Look Normal But You Don't

Approximately 5% of American adults have clinically meaningful thyroid dysfunction. By Peter Attia’s framing in AMA #89, a significant share of them are either undertreated, overtreated, or managed based on an incomplete picture of what thyroid function actually measures.

The TSH Problem

TSH (thyroid-stimulating hormone) is the standard diagnostic marker. Attia’s core technical argument: TSH measures whether the thyroid is receiving stronger or weaker signaling from the pituitary — it’s one step removed from what’s actually happening inside the organs that depend on thyroid hormones.

The thyroid primarily secretes T4, an inactive pro-hormone. T4 converts to active T3 through local enzyme pathways — decisions made tissue by tissue, not system-wide. Your liver’s T3 availability, your brain’s T3 availability, your heart’s T3 availability — these can diverge even when TSH looks normal. A TSH in range doesn’t tell you what’s happening at the tissue level.

This is why patients with “normal” thyroid labs can still have meaningful dysfunction, and why Attia adds free T3 and free T4 to the evaluation rather than stopping at TSH.

The Two Camps (and Why He Rejects Both)

Attia describes two opposing clinical schools:

Over-treatment camp: Treats thyroid dysfunction broadly, attributing a wide range of symptoms (fatigue, cognitive fog, weight gain, mood changes) to thyroid dysfunction even when labs are borderline. This leads to patients on thyroid medication who may not need it.

Under-treatment camp: Only intervenes on obvious cases with unambiguous labs. Patients with subclinical dysfunction or symptoms that don’t fit the classic pattern get dismissed.

His position: “the messy middle ground where the truth probably lies.” Symptoms alone are insufficient for diagnosis — but symptoms plus borderline labs plus response to a therapeutic trial is a different conversation than either camp allows for.

What the Evaluation Actually Looks Like

The diagnostic framework from AMA #89:

• Blood panel including TSH, free T4, and free T3 (not TSH alone)
• Assessment of assay limitations (different lab methodologies produce different reference ranges)
• Differentiation between true hypothyroidism and conditions that mimic it
• For subclinical hypothyroidism: criteria for when to treat vs. monitor

Attia also covers medication timing — thyroid medications have specific absorption considerations that affect whether they actually work, and incorrect timing is a common source of suboptimal outcomes even on the right dose.

When Tests Look Normal and You Don’t

One of the more clinically useful sections addresses patients with persistent symptoms and normal labs: how to interpret that situation, what additional testing might reveal, and how to have a productive conversation with a clinician who is inclined to dismiss the symptoms.

Reverse T3 — a metabolite that can indicate T4-to-T3 conversion problems — is discussed in the context of when it becomes a relevant measurement. (Full detail is behind Attia’s membership paywall; the framework above is from the publicly available episode description.)

Source: Peter Attia MD

Content created with AI assistance and reviewed for accuracy.